Asthma Clinical Trial
Official title:
Modulation of the CysLT1-r Expression Following Allergen Exposure in Non Asthmatic Subjects With Allergic Rhinitis and Mild Allergic Asthmatic Subjects Using the Induced Sputum Technique.
Cysteinyl leukotrienes (CysLTs) play an important role in asthma. CysLTs exert most of their
bronchoconstrictive and pro-inflammatory effects through activation of the CysLT1-r. As
allergic rhinitis appears to be a predisposing factor in the development of asthma and as
CysLT-receptors seem to be implicated in the first steps of asthma manifestations, we think
it would be of interest to determine if the CysLT1-r is a key mediator in the progression
from allergic rhinitis to asthma. We believe it would be interesting to study the expression
of the CysLT1-r
Our goal is to assess baseline, as well as variations following allergen bronchoprovocations,
in the expression of the CysLT1-r in mild asthmatic subjects compared with non asthmatic
subjects with allergic rhinitis.
Our hypothesis is that there will be a higher baseline expression of the CysLT1-r in
asthmatic subjects compared with allergic rhinitis subjects and that allergen
bronchoprovocations will induce an increase in the expression of the CysLT1-r in both groups.
We will recruit mild allergic asthmatic subjects and non asthmatic subjects with allergic
rhinitis. On a baseline visit, allergy skin prick tests, spirometry, methacholine
bronchoprovocation and induced sputum (IS) with differential leukocyte count will be
obtained.
In a second step, mild asthmatic subjects will undergo conventional bronchial allergen
challenge. IS will be obtained at 6h (corresponding to the late asthmatic response) and 24h
following the challenge. The rhinitic subjects and asthmatic subjects will undergo a 4-day
low dose allergen bronchial challenge as well as a nasal allergen challenge. Sputum samples
will be obtained following days 2 and 4 of the low dose challenge and one week later, and 24h
following nasal challenge.
Induced sputum will be analyzed for differential cell count. Total mRNA will be extracted
from IS cells and used for RT-PCR.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|